Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 31.88% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 31.88% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 25.12% from the prior year.
• Other Non-Current Liabilities declined to $1.3 billion in Q1 2026 per VRTX's latest filing, from $1.3 billion in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $1.3 billion in Q4 2025 and bottomed at $115.7 million in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $876.8 million (2024), against an average of $815.6 million.
• Across the five-year window, Other Non-Current Liabilities climbed 6.66% in 2022 and surged 651.34% in 2023, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $685.8 million in 2022, then grew by 27.98% to $877.7 million in 2023, then grew by 15.6% to $1.0 billion in 2024, then climbed by 25.12% to $1.3 billion in 2025, then retreated by 1.11% to $1.3 billion in 2026.
• Per Business Quant, the three latest VRTX Other Non-Current Liabilities figures stand at $1.3 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.2 billion (Q3 2025).